Featured Article
The AAV-based candidate will deliver full-length frataxin (FXN) to treat both brain and heart manifestations of Friedreich’s ataxia, an industry first.
Precision Oncology Today
Magazine
The Importance of Increasing Diversity in Clinical Trials
Before reaching the market, new drugs are tested in people who voluntarily participate in clinical trials. However, for a new medicine to work in as many people as possible, these drugs should be tested in a patient population that is as diverse as possible.
When It Comes to Space Precision Medicine, the Sky Is the Limit—Literally
Based on a growing body of data, some experts believe that pharmacogenomics-guided spaceflight is the foundation of precision medicine, a feature that they believe will enable long-term human habitation on the Moon.
Trending on Inside Precision Medicine
Timberlyne Therapeutics Launched Last Week with a $180 Million Series A Financing
The financing will advance CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38.
New Insights into T-Cell Role in Viral Defense Could Transform Vaccine Strategies
The findings challenge the long-standing assumption that antibodies are the primary defense against acute viral diseases.
Sensitive Tumor DNA Test Effective at Predicting Lung Cancer Progression
A test developed by U.S.-biotech Personalis can pick up small amounts of lung cancer tumor DNA in the blood and predict patient outcomes.
